Progyny (NASDAQ:PGNY) and Pheton (NASDAQ:PTHL) Head-To-Head Review

Pheton (NASDAQ:PTHL) and Progyny (NASDAQ:PGNY) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, dividends, valuation, earnings and risk.

Analyst Ratings

This is a summary of recent ratings for Pheton and Progyny, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pheton	1	0	0	0	1.00
Progyny	0	3	11	0	2.79

Progyny has a consensus target price of $29.67, suggesting a potential upside of 13.75%. Given Progyny’s stronger consensus rating and higher possible upside, analysts clearly believe Progyny is more favorable than Pheton.

Profitability

This table compares Pheton and Progyny’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Pheton	N/A	N/A	N/A
Progyny	5.23%	13.34%	9.03%

Volatility and Risk

Pheton has a beta of 5.4, meaning that its stock price is 440% more volatile than the S&P 500. Comparatively, Progyny has a beta of 1.03, meaning that its stock price is 3% more volatile than the S&P 500.

Institutional and Insider Ownership

94.9% of Progyny shares are held by institutional investors. 9.9% of Progyny shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Pheton and Progyny”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pheton	$305,215.00	6.75	-$660,000.00	N/A	N/A
Progyny	$1.29 billion	1.59	$58.52 million	$0.77	33.87

Progyny has higher revenue and earnings than Pheton.

Summary

Progyny beats Pheton on 10 of the 12 factors compared between the two stocks.

About Pheton

Pheton Holdings Ltd. operates as a holding company with interests in providing healthcare solutions. The firm through its subsidiaries engages in the development and commercialization of brachytherapy TPS specifically used for radioactive particle implantation, a type of radiotherapy used in treating cancer patients by placing radioactive sources inside the patient that kill cancer cells and shrink tumors. The company was founded in 1998 and is headquartered in Beijing, China.

About Progyny

Progyny, Inc., a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides its members with access to the medications needed during their treatment. In addition, it provides assistance service programs where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.